A composition for improving bone and joint health, its preparation method and application

Abstract

This invention provides a composition for improving bone and joint health, its preparation method, and its application, relating to the field of bone and joint health products technology. By weight, the composition for improving bone and joint health comprises the following components: 0.5-5 parts collagen peptides, 5-30 parts mangosteen extract, 0.5-3 parts non-denatured type II collagen peptides, 0.1-2 parts milk mineral salts, 0.3-3 parts bone collagen peptides, 0.1-2 parts cartilage extract, 0.1-2 parts N-acetylglucosamine, 0.1-2 parts sodium hyaluronate, and 0.3-3 parts turmeric extract. This invention, through multiple combinations of mangosteen extract and turmeric extract, and cartilage extract and sodium hyaluronate, obtains a composition that is low in cost, highly safe, and has a good effect on the prevention or improvement of bone and joint diseases.

Description

Technical Field

[0001] This invention belongs to the field of bone and joint health products technology, specifically relating to a composition for improving bone and joint health, its preparation method and application. Background Technology

[0002] Osteoarthritis, also known as degenerative osteoarthritis or osteoarthropathy, is a disease caused by the destruction of articular cartilage, resulting in bone pain, stiffness, and limited mobility. It is a relatively common clinical condition, especially prevalent among middle-aged and elderly people, and commonly affects weight-bearing joints such as the knee, spine, hip joints, and interphalangeal joints. Traditional treatment for osteoarthritis involves taking anti-inflammatory and analgesic drugs after onset, commonly including acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs), and opioids. While these drugs can relieve pain symptoms to some extent, they do not address the underlying cause and have significant side effects; long-term use can cause damage to the liver, kidneys, and digestive tract.

[0003] Chinese invention patent application CN109106944A discloses a composition for the prevention and treatment of osteoarthritis and its application. This composition contains non-denatured type II collagen and chondroitin peptides, with the preferred weight ratio of the non-denatured type II collagen to the chondroitin peptides being 1:1.5-6. The composition also contains one or more of licorice extract, houttuynia cordata extract, turmeric, and vitamin C. However, due to the high price of non-denatured type II collagen and chondroitin peptides, products made primarily from these ingredients are expensive, and their efficacy needs further improvement.

[0004] Chinese invention patent CN116726141 B discloses a composition for preventing and alleviating osteoarthritis and its application. The composition is made from the following raw materials in parts by weight: Vitamin C 0.5-2 parts, glucosamine derivative 25-37 parts, manganese gluconate 0.3-0.6 parts, dimethyl sulfone 15-30 parts, boron-containing compound 1-1.2 parts, chondroitin sulfate 4.4-10 parts, tartrazine 4-8 parts, collagen peptide powder 4.4-8 parts, Boswellia carterii extract 0.5-5 parts, turmeric extract 1-3 parts, and sodium hyaluronate 0.04-0.15 parts. This invention has good effects on the prevention and treatment of osteoarthritis and has no side effects. However, the dimethyl sulfone contained in the raw materials has carcinogenic, teratogenic, sensitizing, and irritating properties. Long-term use may lead to an imbalance of trace elements in the body, endocrine disorders, and liver and kidney damage. Therefore, its safety needs further improvement.

[0005] Therefore, there is an urgent need to develop a composition that is low in cost, highly safe, and has a good preventive or ameliorative effect on osteoarthritis. Summary of the Invention

[0006] This invention addresses the problems existing in the prior art by providing a composition for improving bone and joint health, its preparation method, and its application. The composition obtained through multiple compoundings of mangosteen extract and turmeric extract, cartilage extract, and sodium hyaluronate is characterized by low cost, high safety, and good preventive or ameliorative effects on bone and joint diseases.

[0007] One objective of this invention is to provide a composition for improving bone and joint health, comprising, by weight, the following components: 0.5-5 parts collagen peptides, 5-30 parts mangosteen extract, 0.5-3 parts non-denatured type II collagen peptides, 0.1-2 parts milk mineral salts, 0.3-3 parts bone collagen peptides, 0.1-2 parts cartilage extract, 0.1-2 parts N-acetylglucosamine, 0.1-2 parts sodium hyaluronate, and 0.3-3 parts turmeric extract.

[0008] Preferably, the composition comprises, by weight parts, the following components: 0.8-3 parts collagen peptide, 5-20 parts mangosteen extract, 1-2.5 parts non-denatured type II collagen peptide, 0.1-1.2 parts milk mineral salt, 0.5-2 parts bone collagen peptide, 0.1-1 part cartilage extract, 0.1-1 part N-acetylglucosamine, 0.1-1 part sodium hyaluronate, and 0.5-2 parts turmeric extract.

[0009] Preferably, the composition comprises, by weight parts, the following components: 2 parts collagen peptide, 15 parts mangosteen extract, 2 parts non-denatured type II collagen peptide, 0.8 parts milk mineral salt, 0.8 parts bone collagen peptide, 0.2 parts cartilage extract, 0.2 parts N-acetylglucosamine, 0.2 parts sodium hyaluronate, and 0.8 parts turmeric extract.

[0010] Preferably, the weight ratio of the mangosteen extract to the cartilage extract is 60-80:1.

[0011] Preferably, the weight ratio of the cartilage extract, sodium hyaluronate, and turmeric extract is 1-3:1-3:6-10.

[0012] Preferably, the composition further includes food-grade excipients.

[0013] Preferably, the excipients are selected from at least one of hydroxypropyl methylcellulose, magnesium stearate, microcrystalline cellulose, sorbitol, citric acid, xanthan gum, sucralose, maltodextrin, soluble starch, and lactose.

[0014] More preferably, the excipients are hydroxypropyl methylcellulose, magnesium stearate, microcrystalline cellulose, and sorbitol.

[0015] A second aspect of the present invention is to provide a method for preparing the above-described composition, comprising the following steps:

[0016] The product is obtained by mixing collagen peptides, mangosteen extract, non-denatured type II collagen peptides, milk mineral salts, bone collagen peptides, cartilage extract, N-acetylglucosamine, sodium hyaluronate, turmeric extract, and food-grade excipients.

[0017] A third aspect of the present invention is to provide the use of the above-described composition or the composition prepared according to the above-described preparation method in the preparation of products for the prevention or improvement of osteoarthritis.

[0018] Preferably, the product is a liquid dosage form, a jelly dosage form, a gel candy, a compressed candy, or a powder.

[0019] Compared with existing technologies, the present invention has the following beneficial effects: The composition obtained by the present invention through multiple compounding of mangosteen extract and turmeric extract, chondroitin extract and sodium hyaluronate is characterized by low cost and high safety, and has a good preventive or ameliorative effect on osteoarthritis. The effect of the composition of the present invention is significantly better than that of the comparative examples and the blank control group. Detailed Implementation

[0020] The following non-limiting embodiments are intended to enable those skilled in the art to gain a more comprehensive understanding of the present invention, but do not limit the invention in any way. The following content is merely an exemplary description of the scope of protection of the present invention, and those skilled in the art can make various changes and modifications to the invention based on the disclosed content, which should also fall within the scope of protection of the present invention.

[0021] It is worth noting that the raw materials used in this invention are all commercially available products, and their sources are not specifically limited.

[0022] Example 1:

[0023] 2 parts collagen peptide, 15 parts mangosteen extract, 2 parts non-denatured type II collagen peptide, 0.8 parts milk mineral salt, 0.8 parts bone collagen peptide, 0.2 parts cartilage extract, 0.2 parts N-acetylglucosamine, 0.2 parts sodium hyaluronate, and 0.8 parts turmeric extract.

[0024] Preparation method:

[0025] The product is obtained by mixing collagen peptides, mangosteen extract, non-denatured type II collagen peptides, milk mineral salts, bone collagen peptides, cartilage extract, N-acetylglucosamine, sodium hyaluronate, and turmeric extract.

[0026] Example 2:

[0027] A composition for improving bone and joint health, comprising, by weight parts: 0.8 parts collagen peptides, 5 parts mangosteen extract, 1 part non-denatured type II collagen peptides, 0.1 parts milk mineral salts, 0.5 parts bone collagen peptides, 0.1 parts cartilage extract, 0.1 parts N-acetylglucosamine, 0.1 parts sodium hyaluronate, and 0.5 parts turmeric extract.

[0028] Preparation method:

[0029] The product is obtained by mixing collagen peptides, mangosteen extract, non-denatured type II collagen peptides, milk mineral salts, bone collagen peptides, cartilage extract, N-acetylglucosamine, sodium hyaluronate, and turmeric extract.

[0030] Example 3:

[0031] A composition for improving bone and joint health, comprising, by weight, the following components: 3 parts collagen peptides, 20 parts mangosteen extract, 2.5 parts non-denatured type II collagen peptides, 1.2 parts milk mineral salts, 2 parts bone collagen peptides, 1 part cartilage extract, 1 part N-acetylglucosamine, 1 part sodium hyaluronate, and 2 parts turmeric extract.

[0032] Preparation method:

[0033] The product is obtained by mixing collagen peptides, mangosteen extract, non-denatured type II collagen peptides, milk mineral salts, bone collagen peptides, cartilage extract, N-acetylglucosamine, sodium hyaluronate, and turmeric extract.

[0034] Comparative Example 1:

[0035] A composition for improving bone and joint health, comprising, by weight parts: 2 parts collagen peptides, 2 parts non-denatured type II collagen peptides, 0.8 parts milk mineral salts, 0.8 parts bone collagen peptides, 0.2 parts cartilage extract, 0.2 parts N-acetylglucosamine, 0.2 parts sodium hyaluronate, and 15.8 parts turmeric extract.

[0036] Preparation method:

[0037] The product is obtained by mixing collagen peptides, non-denatured type II collagen peptides, milk mineral salts, bone collagen peptides, cartilage extract, N-acetylglucosamine, sodium hyaluronate, and turmeric extract.

[0038] The difference between Comparative Example 1 and Example 1 is that Comparative Example 1 does not contain mangosteen extract, but its amount is added to turmeric extract, otherwise it is the same as Example 1.

[0039] Comparative Example 2:

[0040] A composition for improving bone and joint health, comprising, by weight parts: 2 parts collagen peptides, 15.8 parts mangosteen extract, 2 parts non-denatured type II collagen peptides, 0.8 parts milk mineral salts, 0.8 parts bone collagen peptides, 0.2 parts cartilage extract, 0.2 parts N-acetylglucosamine, 0.2 parts sodium hyaluronate, and 0.8 parts turmeric extract.

[0041] Preparation method:

[0042] The product is obtained by mixing collagen peptides, mangosteen extract, non-denatured type II collagen peptides, milk mineral salts, bone collagen peptides, cartilage extract, N-acetylglucosamine, and sodium hyaluronate.

[0043] The only difference from Example 1 is that Comparative Example 2 does not contain turmeric extract, but its amount is added to mangosteen extract; otherwise, it is the same as Example 1.

[0044] Comparative Example 3:

[0045] A composition for improving bone and joint health, comprising, by weight parts: 2 parts collagen peptides, 15 parts mangosteen extract, 2 parts non-denatured type II collagen peptides, 0.8 parts milk mineral salts, 0.8 parts bone collagen peptides, 0.2 parts N-acetylglucosamine, 0.4 parts sodium hyaluronate, and 0.8 parts turmeric extract.

[0046] Preparation method:

[0047] The product is obtained by mixing collagen peptides, mangosteen extract, non-denatured type II collagen peptides, milk mineral salts, bone collagen peptides, N-acetylglucosamine, sodium hyaluronate, and turmeric extract.

[0048] The only difference from Example 1 is that Comparative Example 3 does not contain cartilage extract, but its amount is added to sodium hyaluronate; otherwise, it is the same as Example 1.

[0049] Comparative Example 4:

[0050] A composition for improving bone and joint health, comprising, by weight, the following components: 2 parts collagen peptide, 15 parts mangosteen extract, 2 parts non-denatured type II collagen peptide, 0.8 parts milk mineral salt, 0.8 parts bone collagen peptide, 0.4 parts cartilage extract, 0.2 parts N-acetylglucosamine, and 0.8 parts turmeric extract.

[0051] Preparation method:

[0052] The product is obtained by mixing collagen peptides, mangosteen extract, non-denatured type II collagen peptides, milk mineral salts, bone collagen peptides, cartilage extract, N-acetylglucosamine, and turmeric extract.

[0053] The only difference from Example 1 is that Comparative Example 4 does not contain sodium hyaluronate, but its amount is added to the cartilage extract; otherwise, it is the same as Example 1.

[0054] Comparative Example 5:

[0055] A composition for improving bone and joint health, comprising, by weight parts: 2 parts collagen peptides, 14.2 parts mangosteen extract, 2 parts non-denatured type II collagen peptides, 0.8 parts milk mineral salts, 0.8 parts bone collagen peptides, 1 part cartilage extract, 0.2 parts N-acetylglucosamine, 0.2 parts sodium hyaluronate, and 0.8 parts turmeric extract.

[0056] Preparation method:

[0057] The product is obtained by mixing collagen peptides, mangosteen extract, non-denatured type II collagen peptides, milk mineral salts, bone collagen peptides, cartilage extract, N-acetylglucosamine, sodium hyaluronate, and turmeric extract.

[0058] The only difference from Example 1 is the amount and weight ratio of mangosteen extract and cartilage extract. In Example 1, the amounts of the two extracts were 15 parts and 0.2 parts, respectively, with a weight ratio of approximately 75:1; while in Comparative Example 5, the amounts of the two extracts were 14.2 parts and 1 part, respectively, with a weight ratio of 14.2:1. Everything else is the same as in Example 1.

[0059] Comparative Example 6:

[0060] A composition for improving bone and joint health, comprising, by weight parts: 2 parts collagen peptides, 15 parts mangosteen extract, 2 parts non-denatured type II collagen peptides, 0.8 parts milk mineral salts, 0.8 parts bone collagen peptides, 0.4 parts cartilage extract, 0.2 parts N-acetylglucosamine, 0.4 parts sodium hyaluronate, and 0.4 parts turmeric extract.

[0061] Preparation method:

[0062] The product is obtained by mixing collagen peptides, mangosteen extract, non-denatured type II collagen peptides, milk mineral salts, bone collagen peptides, cartilage extract, N-acetylglucosamine, sodium hyaluronate, and turmeric extract.

[0063] The only difference from Example 1 is the amount and weight ratio of the cartilage extract, sodium hyaluronate, and turmeric extract. In Example 1, the cartilage extract was 0.2 parts, sodium hyaluronate was 0.2 parts, and turmeric extract was 0.8 parts, with a ratio of 2:2:8; while in Comparative Example 6, the cartilage extract was 0.4 parts, sodium hyaluronate was 0.4 parts, and turmeric extract was 0.4 parts, with a ratio of 1:1:1. Everything else is the same as in Example 1.

[0064] Experiment Example 1: Pharmacological Effects on Osteoarthritis

[0065] 1. Experimental grouping: Wistar male rats were randomly divided into normal control group, model control group, positive control group, Examples 1-3 and Comparative Examples 1-6 groups, with 10 rats in each group after 7 days of acclimatization.

[0066] 2. Modeling: 10% papain and 0.03 mol / L L-cysteine ​​were mixed at a 1:1 ratio and allowed to stand for 30 minutes before use. On days 1, 4, and 7 of the experiment, 0.2 mL of the papain mixture was injected into the knee joint cavity of rats in the model control group, positive control group, Examples 1-3, and Comparative Examples 1-6 to induce a rat osteoarthritis model. The normal control group was injected with an equal volume of physiological saline.

[0067] 3. Drug Administration: After modeling, drug administration began on day 8 of the experiment. The positive control group was administered amino acid glucose hydrochloride (Aoteling, manufactured by Ausnutria Pharmaceuticals) by gavage at a dose of 90 mg / kg. Examples 1-3 and Comparative Examples 1-6 were administered the samples of Examples 1-3 and Comparative Examples 1-6 by gavage (the compositions of Examples 1-3 and Comparative Examples 1-6 were dissolved in deionized water before administration). The dosage was 0.08 g of the composition / kg·d. The normal control group and the model control group were administered the same dose of deionized water by gavage. Each rat was administered the sample once daily for 4 weeks. The entire experiment, including modeling and drug administration, lasted for 5 weeks.

[0068] 4. Characterization:

[0069] (1) Observation of general condition of rats: Observe the mental state, hair and food intake of rats.

[0070] (2) Changes in the width of the knee joints of rats: The ankle joint width was measured before modeling, before drug administration, at week 2 of drug administration, and at week 4 of drug administration. The average value of the three measurements was taken, and the joint swelling degree was calculated according to the following formula. Joint swelling degree: Joint swelling degree (mm) = Ankle joint width after inflammation (after drug administration) (mm) - Ankle joint width before inflammation (mm).

[0071] (3) Two hours after the last oral administration, the rats were anesthetized, and physiological saline was injected into the joint cavities of both knees for irrigation. The joint lavage fluid was centrifuged at 1500 r / min for 15 min at 4℃, and the supernatant was separated, aliquoted, and stored at -80℃ for later use. The contents of IL-1β, IL-6 and TNF-α in the lavage fluid were determined according to the instructions of the ELISA kit.

[0072] (4) Determination of glycosaminoglycan (GAGs) content in rat synovial tissue: 24 hours after the last oral administration, rats were sacrificed, and synovial tissue from both knee joints was collected, flash-frozen in liquid nitrogen, and then stored at -80℃ for later use. An appropriate amount of synovial tissue was taken, added to ice-cold physiological saline, and homogenized in an ice bath using a tissue homogenizer to prepare a 2% synovial tissue homogenate. The homogenate was centrifuged (4℃, 3500 r / min, 10 min), and the supernatant was collected for later use. The content of glycosaminoglycans (GAGs) in the synovial tissue was determined according to the manufacturer's instructions using the dimethyl methylene blue spectrophotometric method.

[0073] All experimental data were analyzed using SPSS 17.0 software. Based on the normality and homogeneity of variance of the test data, all data were expressed as mean ± standard deviation (s). The significance of differences between groups was compared using the t-test.

[0074] 5. Results:

[0075] (1) Observation results of general condition of rats

[0076] No rat deaths occurred during the modeling process. After the modeling was completed, except for the normal control group which exhibited normal movement, the rats in the other groups showed lethargy and slight lameness in the knee joints. After 4 weeks of treatment, the normal control group rats showed normal knee joint movement, normal diet and water intake, glossy fur, and quick reflexes; the model control group rats all showed local swelling of the knee joint, reduced movement, decreased diet and water intake, and slowed reflexes. The other treatment groups showed varying degrees of improvement in knee joint swelling, activity level, diet and water intake, and reflexes.

[0077] (2) Results of changes in the width of the bilateral knee joints in rats

[0078] The specific results are shown in Table 1.

[0079] Table 1: Results of swelling in the bilateral knee joints of rats

[0080]

[0081]

[0082] Note: Compared with the normal control group, ## P < 0.01; Compared with the model control group, *P < 0.05, **P < 0.01 for each treatment group; Compared with the group in Example 1, each treatment group & This indicates that P < 0.05. && This indicates that P < 0.01.

[0083] The results in the table show that the model control group and the normal control group had significant differences (P < 0.01), indicating successful modeling. Compared with the model control group, the drugs in Examples 1-3 and Comparative Examples 1-6 all had varying degrees of inhibitory effects on joint swelling. The positive control group and Examples 1-3 showed significant differences compared with the model control group (P < 0.01), while the comparative examples 1-6 showed statistically significant differences compared with the model control group (P < 0.05). Compared with Example 1, Examples 2, 3, and the positive control group showed no statistically significant differences compared with Example 1, while Comparative Examples 5 and 6 showed statistically significant differences compared with Example 1 (P < 0.05), and Comparative Examples 1-4 showed significant differences compared with Example 1 (P < 0.01). This indicates that the composition and ratio of raw materials in this composition affect the inhibitory effect on joint swelling, and the synergistic effect of the composition and ratio of raw materials in the present invention achieves optimal results.

[0084] (3) Effects on the levels of inflammatory factors IL-1β, IL-6 and TNF-α in the lavage fluid of rat knee joints

[0085] Specific values ​​are shown in Table 2.

[0086] Table 2: Effects on the content of inflammatory factors in the lavage fluid of the rat knee joint

[0087]

[0088]

[0089] Note: Compared with the normal control group, **P<0.01; compared with the model control group, each drug administration group # P < 0.05 ## P < 0.01; compared with the group in Example 1, each drug administration group & This indicates that P < 0.05. && This indicates that P < 0.01.

[0090] The results in the table show that the levels of inflammatory factors IL-1β, IL-6, and TNF-α differed significantly between the model control group and the normal control group (P < 0.01). Compared with the model control group, the drugs in the positive control group, Examples 1-3, and Comparative Examples 1-6 all had varying degrees of positive regulatory effects on the levels of IL-1β, IL-6, and TNF-α. Specifically, for the levels of IL-1β and TNF-α, the differences between the positive control group, Examples 1-3, Comparative Example 5, and Comparative Example 6 and the model control group were significant (P < 0.01), and the differences between Comparative Example 1-4 and the model control group were statistically significant (P < 0.05). For the levels of IL-6, the differences between the positive control group, Examples 1-3, and Comparative Example 5 and the model control group were significant (P < 0.01), and the differences between Comparative Example 1-4 and Comparative Example 6 and the model control group were statistically significant (P < 0.05). Compared with Example 1, there were no statistically significant differences between Example 2, Example 3, and the positive control group and Example 1, while there were statistically significant (P < 0.05) or significant (P < 0.01) differences between Comparative Examples 1-6 and Example 1. This indicates that the composition and ratio of raw materials in this composition have a positive regulatory effect on the levels of IL-1β, IL-6, and TNF-α, and the synergistic effect of the composition and ratio of raw materials in the composition of this invention can achieve the optimal effect.

[0091] (4) Effect on the content of glycosaminoglycans (GAGs) in synovial tissue of joints

[0092] Specific values ​​are shown in Table 3.

[0093] Table 3: Effects on the content of glycosaminoglycans (GAGs) in synovial tissue of joints

[0094]

[0095]

[0096] Note: Compared with the normal control group, **P<0.01; compared with the model control group, each drug administration group # P < 0.05 ## P < 0.01; compared with the group in Example 1, each drug administration group & This indicates that P < 0.05. && This indicates that P < 0.01.

[0097] The results in the table show that the content of GAGs differed significantly between the model control group and the normal control group (P < 0.01). Compared with the model control group, the drugs in Examples 1-3 and Comparative Examples 1-6 all had varying degrees of positive regulatory effects on the content of GAGs. Significant differences were found between the positive control group, Examples 1-3, Comparative Example 5, and Comparative Example 6 and the model control group (P < 0.01), while the difference between Comparative Example 1-4 and the model control group was statistically significant (P < 0.05). Compared with Example 1, there were no statistically significant differences between Examples 2, 3, and the positive control group and Example 1, while the differences between Comparative Example 5-6 and Example 1 were statistically significant (P < 0.05), and the differences between Comparative Example 1-4 and Example 1 were significant (P < 0.01). This indicates that the composition and ratio of raw materials in this composition affect the positive regulatory effect on the content of GAGs, and the synergistic effect of the composition and ratio of raw materials in the composition of this invention achieves the optimal effect.

[0098] In summary, the compositions in the embodiments of the present invention have a good inhibitory effect on joint swelling and a significant positive regulatory effect on the content of inflammatory factors IL-1β, IL-6, TNF-α and glycosaminoglycans (GAGs) in the synovial tissue of arthritis model rats. The effects are significantly better than those of the compositions in comparative examples 1-6.

[0099] Preparation example:

[0100] Ingredients: 20g collagen peptides, 150g mangosteen extract, 20g non-denatured type II collagen peptides, 8g milk mineral salts, 8g bone collagen peptides, 2g cartilage extract, 2g N-acetylglucosamine, 2g sodium hyaluronate, 8g turmeric extract, 4g magnesium stearate, 246g microcrystalline cellulose, 10g sorbitol, 20g hydroxypropyl methylcellulose.

[0101] Mix the above ingredients and press them into 1000 candy tablets.

[0102] Finally, it should be noted that the above content is only used to illustrate the technical solution of the present invention, and is not intended to limit the scope of protection of the present invention. Simple modifications or equivalent substitutions made by those skilled in the art to the technical solution of the present invention do not depart from the essence and scope of the technical solution of the present invention.

Claims

1. A composition for improving bone and joint health, comprising, by weight parts: 0.8-3 parts collagen peptides, 5-20 parts mangosteen extract, 1-2.5 parts undenatured type II collagen peptides, 0.1-1.2 parts milk mineral salts, 0.5-2 parts bone collagen peptides, 0.1-1 part cartilage extract, 0.1-1 part N-acetylglucosamine, 0.1-1 part sodium hyaluronate, and 0.5-2 parts turmeric extract; wherein... The weight ratio of mangosteen extract to cartilage extract is 60-80:1; The weight ratio of the cartilage extract, sodium hyaluronate, and turmeric extract is 1-3:1-3:6-10.

2. The composition according to claim 1, characterized in that, The composition comprises, by weight parts: 2 parts collagen peptide, 15 parts mangosteen extract, 2 parts non-denatured type II collagen peptide, 0.8 parts milk mineral salt, 0.8 parts bone collagen peptide, 0.2 parts cartilage extract, 0.2 parts N-acetylglucosamine, 0.2 parts sodium hyaluronate, and 0.8 parts turmeric extract.

3. The use of the composition according to any one of claims 1-2 in the preparation of a product for preventing or improving osteoarthritis.

Images